Mineral wool

External Wall Insulation Board Market to Hit $14.9 Million, by 2030 at 8.3% CAGR: Coherent Market Insights

Retrieved on: 
Wednesday, March 27, 2024
BASF, Growth, Saint-Gobain, Mineral wool, Formaldehyde, Knauf Insulation, Ageing, Home construction

Another market opportunity in the External Wall Insulation Board market is the growing trend of renovation and retrofitting projects, driving the demand for these insulation solutions.

Key Points: 
  • Another market opportunity in the External Wall Insulation Board market is the growing trend of renovation and retrofitting projects, driving the demand for these insulation solutions.
  • With aging buildings in need of energy efficiency upgrades and increased awareness about the benefits of external wall insulation, the market for insulation boards is witnessing significant growth.
  • Additionally, the external thermal insulation composite systems (ETICS) segment is dominating the market by position, offering a comprehensive solution for external wall insulation requirements.
  • In terms of position, the external thermal insulation composite systems (ETICS) segment is dominating the market, providing a comprehensive solution for external wall insulation.

External Wall Insulation Board Market to Hit $14.9 Million, by 2030 at 8.3% CAGR: Coherent Market Insights

Retrieved on: 
Wednesday, March 27, 2024
BASF, Growth, Saint-Gobain, Mineral wool, Formaldehyde, Knauf Insulation, Ageing, Home construction

Another market opportunity in the External Wall Insulation Board market is the growing trend of renovation and retrofitting projects, driving the demand for these insulation solutions.

Key Points: 
  • Another market opportunity in the External Wall Insulation Board market is the growing trend of renovation and retrofitting projects, driving the demand for these insulation solutions.
  • With aging buildings in need of energy efficiency upgrades and increased awareness about the benefits of external wall insulation, the market for insulation boards is witnessing significant growth.
  • Additionally, the external thermal insulation composite systems (ETICS) segment is dominating the market by position, offering a comprehensive solution for external wall insulation requirements.
  • In terms of position, the external thermal insulation composite systems (ETICS) segment is dominating the market, providing a comprehensive solution for external wall insulation.

Stryve Foods, Inc. Reports Third Quarter Fiscal 2023 Results

Retrieved on: 
Tuesday, November 14, 2023
EBITDA, Absorption, Jan Frans De Boever, Rationalization, GAAP, CPG, ATM, Growth, Average cost, SKU, Retail, Bank, Video game, Reinsurance, Insurance, Bookkeeping, Mineral wool

PLANO, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snack and eating platform disrupting traditional consumer packaged goods (CPG) categories, and a leader in the air-dried meat snack industry in the United States, today reports financial and operating results for the three months and nine months ended September 30, 2023.

Key Points: 
  • Adjusted loss per share3 of ($1.66) for the third quarter of 2023, which compares favorably to adjusted loss per share of ($2.21) for the year-ago period.
  • Adjusted EBITDA loss3 of ($2.5) million for the 2023 third quarter, compared to ($3.9) million in the prior year quarter.
  • The Company will conduct a conference call today at 4:30 p.m. Eastern Time to discuss financial and operating results for the third quarter ended September 30, 2023.
  • A telephonic replay will be available through November 28, 2023, by calling (844) 512-2921 and using passcode ID:148214195.

New THC Gummies Unveiled by The Hemp Doctor: Kayo Rapid Release and Downshift

Retrieved on: 
Friday, December 15, 2023
Sleep, Cannabinoid, Hemp, Nano, Safety, Hemp oil, Space Delta 9, Edible, THC, Gummy candy, CBN, Delta 8, Energy, THCV, CBC, System, Relaxation, CBG, Pharmaceutical industry, Birth control, Typesetting, Aroma compound, Mineral wool, Gum arabic, D9, CBD, Delta, Nanotechnology

MOORESVILLE, N.C., Dec. 15, 2023 /PRNewswire-PRWeb/ -- Kayo Rapid Release Gummies: Tailored Experiences, Instant Gratification

Key Points: 
  • The Hemp Doctor, a leading name in the CBD industry, is proud to announce the launch of two revolutionary THC gummy products: Kayo Rapid Release and Downshift Gummies.
  • MOORESVILLE, N.C., Dec. 15, 2023 /PRNewswire-PRWeb/ -- Kayo Rapid Release Gummies: Tailored Experiences, Instant Gratification
    Enjoy The Hemp Doctor's Kayo Rapid Release Nano THC Gummies , a ground-breaking product that perfectly balances taste and wellness in each delicious mouthful!
  • Another exciting addition to The Hemp Doctor's product line-up is the improved Downshift Gummies .
  • With Kayo Rapid Release and Downshift Gummies the Hemp Doctor invites consumers to experience a new era of THC gummy excellence.

Ever.Ag Launches Enable, a New Capability in the FieldAlytics Platform, Built to Leverage Spatial and Transactional Data

Retrieved on: 
Wednesday, November 29, 2023
Agribusiness, Enabling, Agriculture, AG, CRM, Health, Workflow, Conference, ERPs, Software, Forecasting, ERP, Soil, Mineral wool, Sales

LEWISVILLE, Texas, Nov. 29, 2023 /PRNewswire/ -- Ever.Ag, a leader in software for everything agriculture, is proud to announce their latest innovation: FieldAlytics Enable. This addition to the FieldAlytics platform is not just a sales enablement tool; it's a comprehensive solution that transforms the way sales agronomists work. By integrating rich spatial and transactional data, FieldAlytics Enable goes beyond traditional CRM capabilities, offering a unique and essential resource for the agricultural market.

Key Points: 
  • LEWISVILLE, Texas, Nov. 29, 2023 /PRNewswire/ -- Ever.Ag, a leader in software for everything agriculture, is proud to announce their latest innovation: FieldAlytics Enable.
  • This addition to the FieldAlytics platform is not just a sales enablement tool; it's a comprehensive solution that transforms the way sales agronomists work.
  • By integrating rich spatial and transactional data, FieldAlytics Enable goes beyond traditional CRM capabilities, offering a unique and essential resource for the agricultural market.
  • "It's the first of its kind to merge spatial and transactional data in a user-friendly application.

Travis Perkins plc: Refinancing completed with renewal of £375m revolving credit facility

Retrieved on: 
Thursday, December 14, 2023
RCF, Mineral wool, Self storage

The renewed £375m RCF is for a five-year term with two extension options of one year each and is provided by a syndicate of eight banks on broadly comparable terms to the 2019 RCF.

Key Points: 
  • The renewed £375m RCF is for a five-year term with two extension options of one year each and is provided by a syndicate of eight banks on broadly comparable terms to the 2019 RCF.
  • The RCF also incorporates an accordion feature.
  • The Group’s committed debt facilities now total £800m with details shown below:

Formulating for Gut Health with Bio Hemp Fiber Crisps, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, November 9, 2023
PGP, Mineral wool

TORONTO, Nov. 9, 2023 /PRNewswire-PRWeb/ -- Discover an innovative webinar delving into the potential of the fiber-forward market and the importance of fiber-enriched applications for holistic gut health. The market opportunity for fiber-forward products and support for gut health continues to be significant. In the US alone, if consumers closed the opportunity gap in fiber-enriched formulation, and consumers met the daily average recommended intake levels, the total market for foods fortified with more than six grams of fiber could grow to more than $12 billion annually.

Key Points: 
  • Attendees will learn about the benefit of bioactives and fiber for gut health.
  • The featured speakers will discuss how PGP's Bio Hemp Fiber Crisp is a possibility to bring a new fiber component to your plant-based, better-for-you, food products.
  • PGP International has developed a Bio Hemp Fiber Crisp that delivers an innovative upcycled fiber source in a crunchy, rice-based crisp that is ready for fiber-forward, gut health-focused product inclusion.
  • Both types of fiber serve different needs and have different sensory effects and both are essential to a holistic approach to gut health.

Custodian Property Income REIT plc: Second quarter trading update shows rental growth supporting fully covered dividends and stable values

Retrieved on: 
Tuesday, November 7, 2023
Achieved, International, Next, Lloyd, International Financial Reporting Standards, Jack Wills, Pride Park, LTV, Administration, REIT, ERV, Growth, Investment, WAULT, Aviva, Attitude, History, NAV, Community, EPRA, Movement, Shotley Bridge, Blue Cross, Holding company, Mineral wool, Renting, Security (finance), Lease, Commercial property, Silviculture, Rare-earth element, Bank, Halfords

The outcome for the NAV of Custodian Property Income REIT has been a marginal decrease of 3.9% over the past three quarters.

Key Points: 
  • The outcome for the NAV of Custodian Property Income REIT has been a marginal decrease of 3.9% over the past three quarters.
  • It is the strength of the occupational market driving rental growth and low vacancy that will ultimately support fully covered dividends and earnings growth.
  • Income/earnings remain a central focus for Custodian Property Income REIT, and it is income that will deliver positive total returns for shareholders.
  • The Board has approved an interim dividend per share of 1.375p for the Quarter, fully covered by EPRA earnings, payable on 30 November 2023.

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Retrieved on: 
Saturday, November 4, 2023
Patient, APRIL, Hematuria, EGFR, Tetanus, Diphtheria, Immunoglobulin A, Poster, Society, American Society of Nephrology, BAFF, Disease, COVID-19, Risk, Immunity, ASN, Kidney disease, Safety, Overalls, UPCR, Therapy, Kidney, Death, Infection, Proteinuria, Mineral wool, Pharmaceutical industry, Vaccine, IgA nephropathy

BRISBANE, Calif., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the presentation of three posters – including an additional analysis of week 36 data from the Phase 2b ORIGIN study demonstrating resolution of hematuria in the majority of patients – on the Company’s product candidate atacicept in patients with immunoglobulin A nephropathy (IgAN) at the American Society of Nephrology (ASN) Kidney Week 2023, in Philadelphia, PA.

Key Points: 
  • Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves hematuria in the majority of patients.
  • Additional poster presentations provide further safety analysis of Phase 2b and details of pivotal Phase 3 clinical trial design, which is currently enrolling.
  • At week 36 of the ORIGIN Phase 2b study of atacicept in patients with IgAN, hematuria resolved in 80% of patients (n=12/15) receiving atacicept 150 mg compared to 5% (n=1/19) in the placebo group.
  • Through the randomized, placebo-controlled period, infections were balanced between atacicept and placebo in both the Phase 2a JANUS and Phase 2b ORIGIN studies.

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Apolipoprotein E, Amyloid, Research, Acute myeloid leukemia, Plaque, Public expenditure, Conference, American Society for Bone and Mineral Research, Society, Osteoporosis, Mouse, ADC, Osteogenesis imperfecta, Annual general meeting, Cancer, Patient, AML, Mineral wool, Pharmaceutical industry, Cryptocurrency

Financial Results for Quarter Ended September 30, 2023

Key Points: 
  • Financial Results for Quarter Ended September 30, 2023
    Cash, cash equivalents, and marketable securities as of September 30, 2023, were $118.2 million as compared to $159.9 million as of December 31, 2022.
  • Research and development expenses were $11.0 million for the quarter ended September 30, 2023, as compared to $13.5 million for the quarter ended September 30, 2022.
  • General and administrative expenses were $4.6 million for the quarter ended September 30, 2023, as compared to $5.7 million for the quarter ended September 30, 2022.
  • Net loss was $14.3 million for the quarter ended September 30, 2023, as compared with a net loss of $18.9 million for the quarter ended September 30, 2022.